TEST: 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE GENE MUTATION
(MTHFR C677T)

PRINCIPLE:
Severe 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency is
an autosomal recessive disorder and the most common inborn error of folate metabolism. MTHFR polymorphism is the result of a missense
mutation at nucleotide position 677, C to T substitution, in the MTHFR
gene. This mutation replaces Ala677 (GCC) with Val (GTC), thereby creating an HinfI site. Homozygosity or heterozygosity for the MTHFR mutation result in reduced enzymatic activity
and decreased synthesis of 5-methyltetrahydrofolate, the primary methyl donor in the conversion
of homocysteine to methionine, which causes hyperhomocysteinemia, homocystinuria and hypomethioninemia. Increased plasma levels of homocysteine are risk factors for venous and arterial thrombosis as well as cardiovascular and neurologic diseases. Hyperhomocysteinemia has been reported in women with recurrent spontaneous abortion, thus MTHFR polymorphism may be a risk factor for unexplained pregnancy loss. Underlying maternal vascular disease augments the risk for preeclampsia, one of the most common and serious complications of pregnancy. The MTHFR mutation is more prevalent in women with severe preeclampsia and increases the risk associated with the FV Leiden mutation for deep-vein thrombosis. Mutation in MTHFR gene is rather common and can be detected by molecular analysis.

SPECIMEN REQUIREMENTS:
10mL whole blood collected in lavender top EDTA tubes (two 5ml tubes). Specimen should be delivered to the laboratory within 72 hours at room temperature. Peripheral blood specimens that are clotted, have not been collected in EDTA, or frozen are not acceptable.

METHOD:
Polymerase Chain Reaction (PCR) and reverse hybridization.

REFERENCES:
10:111-113.
Pavone, G. Di Minno. 1997 Factor V Leiden, C T MTHFR polymorphism and genetic susceptibility
to preeclampsia. Thromb Haemost 77:1052-1054.
1999 Increased frequency of genetic thrombophilia in women with complications of pregnancy. N.

Normal Range: Reported as: Normal, Heterozygous Mutated, or Homozygous Mutated

Turnaround time: 10 business days